Alto Neuroscience (ANRO) Times Interest Earned (2023 - 2026)
Alto Neuroscience (ANRO) posted Times Interest Earned of -$49.79 for Q1 2026, down 170.07% sequentially from $71.06 in Q4 2025, and down 535.3% YoY from $11.44 in Q1 2025.
Powered by 
Analysis
Alto Neuroscience (ANRO) Times Interest Earned (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Times Interest Earned for 4 years, with the latest figure at -$49.79 in Q1 2026.
- Quarterly Times Interest Earned fell 535.3% year-over-year to -$49.79 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$119.18 (down 241.01% YoY) and the FY2025 annual result came in at -$1.27, up 30.62% from the prior year.
- Times Interest Earned slipped to -$49.79 in Q1 2026 per ANRO's latest filing, from $71.06 in the prior quarter.
- Over five years, Times Interest Earned peaked at $16997.0 in Q4 2024 and troughed at -$54.11 in Q3 2024.
- A 4-year average of $1301.1 and a median of -$22.23 in 2023 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2024 and 2026: Times Interest Earned surged 14636.03% in 2024, then tumbled 535.3% in 2026.
- Over 4 years, Times Interest Earned stood at $115.34 in 2023, then soared by 14636.03% to $16997.0 in 2024, then slumped by 99.58% to $71.06 in 2025, then plunged by 170.07% to -$49.79 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$49.79, $71.06, and -$0.01 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Alto Neuroscience | 1.52 Bn | 1.52 Bn | - | -59.33 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -59.33 |
| Mar 31, 2026 | -49.79 |
| Dec 31, 2025 | -29.66 |
| Sep 30, 2025 | -23.00 |
| Jun 30, 2025 | -28.92 |
| Mar 31, 2025 | -26.21 |
| Dec 31, 2024 | -51.04 |
| Sep 30, 2024 | -54.11 |
| Jun 30, 2024 | -52.86 |
| Mar 31, 2024 | -41.58 |
| Dec 31, 2023 | -33.05 |
| Sep 30, 2023 | -26.77 |
| Jun 30, 2023 | -27.91 |
| Mar 31, 2023 | -22.23 |